Research ArticleTheranostics
Biodistribution, Pharmacokinetics, and Dosimetry of 177Lu-, 90Y-, and 111In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist 177Lu-DOTATATE: The Mass Effect
Guillaume P. Nicolas, Rosalba Mansi, Lisa McDougall, Jens Kaufmann, Hakim Bouterfa, Damian Wild and Melpomeni Fani
Journal of Nuclear Medicine September 2017, 58 (9) 1435-1441; DOI: https://doi.org/10.2967/jnumed.117.191684
Guillaume P. Nicolas
1Division of Nuclear Medicine, University Hospital of Basel, Basel, Switzerland
2Center for Neuroendocrine and Endocrine Tumors, University Hospital of Basel, Basel, Switzerland
Rosalba Mansi
3Division of Radiopharmaceutical Chemistry, University Hospital of Basel, Basel, Switzerland; and
Lisa McDougall
1Division of Nuclear Medicine, University Hospital of Basel, Basel, Switzerland
3Division of Radiopharmaceutical Chemistry, University Hospital of Basel, Basel, Switzerland; and
Jens Kaufmann
4OctreoPharm Sciences GmbH, Ipsen Group, Berlin, Germany
Hakim Bouterfa
4OctreoPharm Sciences GmbH, Ipsen Group, Berlin, Germany
Damian Wild
1Division of Nuclear Medicine, University Hospital of Basel, Basel, Switzerland
2Center for Neuroendocrine and Endocrine Tumors, University Hospital of Basel, Basel, Switzerland
Melpomeni Fani
1Division of Nuclear Medicine, University Hospital of Basel, Basel, Switzerland
3Division of Radiopharmaceutical Chemistry, University Hospital of Basel, Basel, Switzerland; and
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 58, Issue 9
September 1, 2017
Biodistribution, Pharmacokinetics, and Dosimetry of 177Lu-, 90Y-, and 111In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist 177Lu-DOTATATE: The Mass Effect
Guillaume P. Nicolas, Rosalba Mansi, Lisa McDougall, Jens Kaufmann, Hakim Bouterfa, Damian Wild, Melpomeni Fani
Journal of Nuclear Medicine Sep 2017, 58 (9) 1435-1441; DOI: 10.2967/jnumed.117.191684
Biodistribution, Pharmacokinetics, and Dosimetry of 177Lu-, 90Y-, and 111In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist 177Lu-DOTATATE: The Mass Effect
Guillaume P. Nicolas, Rosalba Mansi, Lisa McDougall, Jens Kaufmann, Hakim Bouterfa, Damian Wild, Melpomeni Fani
Journal of Nuclear Medicine Sep 2017, 58 (9) 1435-1441; DOI: 10.2967/jnumed.117.191684
Jump to section
Related Articles
Cited By...
- Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study
- Comparison of the tolerability of terbium-161 and lutetium-177 in combination with somatostatin analogues in the preclinical setting
- Head-to-Head Comparison of 68Ga-NODAGA-JR11 and 68Ga-DOTATATE PET/CT in Patients with Metastatic, Well-Differentiated Neuroendocrine Tumors: Interim Analysis of a Prospective Bicenter Study
- 225Ac-MACROPATATE: A Novel {alpha}-Particle Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors
- First-in-Humans Study of the SSTR Antagonist 177Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy
- A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in Patients with Well-Differentiated Neuroendocrine Tumors
- Multimodal Imaging of 2-Cycle PRRT with 177Lu-DOTA-JR11 and 177Lu-DOTATOC in an Orthotopic Neuroendocrine Xenograft Tumor Mouse Model
- Head-to-Head Comparison of 68Ga-DOTA-JR11 and 68Ga-DOTATATE PET/CT in Patients with Metastatic, Well-Differentiated Neuroendocrine Tumors: A Prospective Study
- New Developments in Peptide Receptor Radionuclide Therapy
- International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature
- Somatostatin Receptor Imaging of Neuroendocrine Tumors: From Agonists to Antagonists
- Safety, Biodistribution, and Radiation Dosimetry of 68Ga-OPS202 in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study
- Advantages and Limits of Targeted Radionuclide Therapy with Somatostatin Antagonists
- Reply: Advantages and Limits of Targeted Radionuclide Therapy with Somatostatin Antagonists